Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions


ACTA Fails To Become EU Law

July 2012 | Industry Trend Analysis

BMI View: The European parliament's rejection of the Anti-Counterfeiting Trade Agreement (ACTA) is moderately bad news for innovative drugmakers but positive for generic drug producers that have operations within or through the EU but sell in developing markets.

To read the full article, please choose one of the following options:

Subcribers please log in

Western Europe InsightWestern Europe Channels Western Europe Countries